D-penicillamine induced myasthenia gravis in rheumatoid arthritis: An unpredictable common occurrence?
| Autor: | T. Papapetropoulos, C. A. Papasteriades, E. Terzis, A. P. Andonopoulos, E. Tsibri |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Male
Drug medicine.medical_specialty HLA-DR1 media_common.quotation_subject Population Arthritis Rheumatoid Rheumatology HLA Antigens Internal medicine Myasthenia Gravis medicine Humans Sex Distribution education Aged media_common education.field_of_study business.industry Penicillamine General Medicine Middle Aged medicine.disease Myasthenia gravis Discontinuation Pyridostigmine Rheumatoid arthritis Immunology Female business medicine.drug |
| Zdroj: | Clinical Rheumatology. 13:586-588 |
| ISSN: | 1434-9949 0770-3198 |
| DOI: | 10.1007/bf02242998 |
| Popis: | Five patients out of 71 with rheumatoid arthritis (RA), who received D-penicillamine, developed myasthenia gravis (MG) within a two-year period. They all responded promptly to discontinuation of the drug and pyridostigmine administration. None of the patients had anti-Ro(SSA) antibodies or features of Sjögren's syndrome, whereas three of the five had the HLA-DR1 phenotype. The relatively high frequency of MG observed in our population, along with its unpredictability and potentially serious sequelae, necessitates its inclusion in the list of side effects of D-penicillamine routinely discussed with the patient, prior to initiation of the treatment. Full alertness of both the patient and the physician to even minor initial myasthenic symptoms, that dictate immediate discontinuation of the drug, is of obvious importance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink